GT Biopharma, Inc.GTBP
Price (close)
$6.83
Market cap
$308.1M
P/E
—
Revenue (TTM)
—
Net income
-$4.8M
Dividend yield
—
1-year total return
797.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What GT Biopharma, Inc. does.
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
fusion protein immune cell engager technology platforms. Our TriKE ® and Dual Targeting TriKE® platforms generate proprietary
therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — | — |
| Net income | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| Free cash flow | — | — | — | — | — | — |
More on GTBP.
- GT Biopharma, Inc. summary
- GT Biopharma, Inc. financial statements
- GT Biopharma, Inc. key metrics
- GT Biopharma, Inc. health scores and style box
- GT Biopharma, Inc. earnings
- GT Biopharma, Inc. dividends
- GT Biopharma, Inc. valuation
- GT Biopharma, Inc. ownership and insiders
- GT Biopharma, Inc. peers
Figures from GT Biopharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.